Covid-19. Aspirin reduces the need for ICU and ventilators by 44%
An important update on covid-19 cures. The Washington State university has discovered that aspirin can reduce the need for ventilation by 40%, ICU admissions by 44% and death by 40%. It also has immune boosting functions and can reduce your chances of ever getting Covid-19 by 20%. This is science from Washington State University and the Barzilai Health Center in Israel. Wow.
Usual doses for mild to moderate pain are 350 or 650 mg every 4 hours or 500 mg every 6 hours.
- Doses for rheumatoid arthritis include 500 mg every 4-6 hours; 650 mg every 4 hours; 1000 mg every 4-6 hours; 1950 mg twice daily.
Aspirin Use May Decrease Ventilation, ICU Admission and Death in COVID-19 Patients
George Washington researchers found that aspirin may have lung-protective effects and reduce in-hospital mortality in hospitalized COVID-19 patients.
George Washington University researchers found low dose aspirin may reduce the need for mechanical ventilation, ICU admission and in-hospital mortality in hospitalized COVID-19 patients, according to a new study.
“As we learned about the connection between blood clots and COVID-19, we knew that aspirin—used to prevent stroke and heart attack—could be important for COVID-19 patients,” said Jonathan Chow, assistant professor of anesthesiology and critical care medicine and director of the Critical Care Anesthesiology Fellowship at the GW School of Medicine and Health Sciences. “Our research found an association between low dose aspirin and decreased severity of COVID-19 and death.”
More than 400 patients hospitalized from March to July 2020 around the United States were included in the study, including patients admitted to GW Hospital, the University of Maryland Medical Center, Wake Forest Baptist Medical Center and Northeast Georgia Health System.
After adjusting for demographics and comorbidities, aspirin use was associated with a decreased risk of mechanical ventilation (44% reduction), ICU admission (43% reduction) and in-hospital mortality (47% reduction). There were no differences in major bleeding or overt thrombosis between aspirin users and non-aspirin users.
Preliminary findings were first published as a preprint in fall 2020. Since then, other studies have confirmed the impact aspirin can have on both preventing infection and reducing risk for severe COVID-19 and death. Dr. Chow hopes this study leads to more research on whether a causal relationship exists between aspirin use and reduced lung injury in COVID-19 patients.
“Aspirin is low cost, easily accessible and millions are already using it to treat their health conditions,” Dr. Chow said. “Finding this association is a huge win for those looking to reduce risk from some of the most devastating effects of COVID-19.”
In addition to Dr. Chow, study authors include David Yamane, assistant professor of emergency medicine and anesthesiology and critical care medicine at the SMHS; Ivy Benjenk, lead research coordinator for the department of anesthesiology and critical care medicine at GW Hospital; and Shannon Cain, a third-year resident in the department of emergency medicine at SMHS; as well as researchers from the University of Maryland Medical Center, Wake Forest Baptist Medical Center and Northeast Georgia Health System.
The study was published in Anesthesia & Analgesia on March 17.
The Israel Study
Coronavirus: Aspirin may help prevent infection, Israeli study shows
“This observation of the possible beneficial effect of low doses of aspirin on COVID-19 infection is preliminary but seems very promising,” Prof. Eli Magen from the Barzilai Medical Center said.
The use of aspirin might help prevent becoming infected with corona and shorten the duration of the disease, a study conducted by a joint team from Leumit Health Care Services, Bar-Ilan University and Barzilai Medical Center has shown.
The study, whose findings were published in the FEBS Journal of the Federation of European Biochemical Societies, analyzed data from some 10,000 Israelis who were tested for COVID-19 between February 1 and June 30, 2020.
The researchers compared those who regularly take a low dose of aspirin as a medication to prevent and treat cardiovascular diseases with those who don’t.
They found that the former group was 29% less likely to become infected with the virus than the latter.
“This observation of the possible beneficial effect of low doses of aspirin on COVID-19 infection is preliminary but seems very promising,” Prof. Eli Magen from the Barzilai Medical Center, who led the study, said in a press release.
Aware of its established positive influence on the immune system in the fight against some viral infections, the team decided to explore the possible effect of its properties against COVID-19.
The researchers also observed that those who took aspirin and contracted the disease recovered on average two or three days faster than individuals who did not, depending on preexisting conditions. In addition, the time it took these patients to test negative for the virus after testing positive was significantly lower.
The physicians said that they intend to continue exploring this issue.
“The present study sought to better understand the potential favorable effects of aspirin in aiding the human immune system to battle COVID-19,” according to Dr. Milana Frenkel-Morgenstern of the Azrieli Faculty of Medicine of Bar-Ilan University. “We intend to investigate a larger cohort of patients and in randomized clinical trials”
Medications based on acetylsalicylic acid – aspirin’s essential component – are used to reduce pain, fever and inflammation and have been known since ancient times. The name was invented by the pharmaceutical company Bayer at the end of the 19th century. Aspirin is one of the most popular drugs in the world.
- Home
- Search Results
- Study Record Detail
Save this study
Protective Effect of Aspirin on COVID-19 Patients (PEAC)
| The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04365309 |
| Recruitment Status : Enrolling by invitation First Posted : April 28, 2020 Last Update Posted : April 28, 2020 |
Sponsor:
Xijing Hospital
Information provided by (Responsible Party):
Xijing Hospital
Study Description
Go to
Brief Summary:
COVID-19 has a high infection rate and mortality, and serious complications such as heart injury cannot be ignored. Cardiac dysfunction occurred in COVID-19 patients, but the law and mechanism of cardiac dysfunction remains unclear. The occurrence of progressive inflammatory factor storm and coagulation dysfunction in severe and fatal cases of NCP points out a new direction for reducing the incidence of severe and critically ill patients, shortening the length of duration in severe and critically ill patients and reducing the incidence of complications of cardiovascular diseases. Aspirin has the triple effects of inhibiting virus replication, anticoagulant and anti-inflammatory, but it has not received attention in the treatment and prevention of NCP. Although Aspirin is not commonly used in the guidelines for the treatment of NCP, it was widely used in the treatment and prevention of a variety of human diseases after its first synthesis in 1898. Subsequently, aspirin has been confirmed to have antiviral effect on multiple levels. Moreover, one study has confirmed that aspirin can inhibit virus replication by inhibiting prostaglandin E2 (PGE2) in macrophages and upregulation of type I interferon production. Subsequently, pharmacological studies have found that aspirin as an anti-inflammatory and analgesic drug by inhibiting cox-oxidase (COX). Under certain conditions, the platelet is the main contributor of innate immune response, studies have found that in the lung injury model in dynamic neutrophil and platelet aggregation.
In summary, the early use of aspirin in covid-19 patients, which has the effects of inhibiting virus replication, anti-platelet aggregation, anti-inflammatory and anti-lung injury, is expected to reduce the incidence of severe and critical patients, shorten the length of hospital duration and reduce the incidence of cardiovascular complications.
| Condition or disease | Intervention/treatment | Phase |
| Novel Coronavirus PneumoniaAspirinTreatment | Drug: Aspirin 100mg | Phase 2Phase 3 |
Show detailed description
Study Design
Go to
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 128 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Protective Effect of Aspirin on COVID-19 Patients |
| Actual Study Start Date : | February 10, 2020 |
| Estimated Primary Completion Date : | April 2020 |
| Estimated Study Completion Date : | June 2020 |
Resource links provided by the National Library of Medicine
Drug Information available for: Aspirin
Arms and Interventions
Go to
| Arm | Intervention/treatment |
| No Intervention: the NCP standard treatment group According to the diagnosis and treatment guidelines, the patients were divided into four types: mild, common, severe and critically ill. Then patients with common and severe ill were randomly divided into two groups, respectively, namely the NCP standard treatment group and the NCP aspirin group (aspirin 100 mg/d, oral + combined standard treatment). | |
| Experimental: the NCP aspirin treatment group According to the diagnosis and treatment guidelines, the patients were divided into four types: mild, common, severe and critically ill. Then patients with common and severe ill were randomly divided into two groups, respectively, namely the NCP standard treatment group and the NCP aspirin group (aspirin 100 mg/d, oral + combined standard treatment). Patients in the NCP aspirin group were given aspirin 100 mg/d orally after admission and aspirin for 14 days after discharge. | Drug: Aspirin 100mg on the bases of standard treatment for the COVID-19, low-dose aspirin (100 mg/ day), orally，is added to. Other Name: Oxygen therapy, antiviral treatment and other support treatments |
Outcome Measures
Go to
Primary Outcome Measures :
- clinical recovery time (TTCR) [ Time Frame: not more than 14 days ]
TTCR is defined as the study treatment (oral aspirin enteric-coated tablet) began to fever, breathing rate, blood oxygen saturation recovery, and cough relieving for at least 72 hours. - the time of SARS-CoV2 overcasting [ Time Frame: not more than 37 days ]
Time of SARS-CoV2 in upper respiratory tract specimens overcasting detected by RT-PCR.
Eligibility Criteria
Go to
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- The patient volunteered to participate in the study, approved the aspirin treatment, and was willing to randomly accept one of the aspirin treatment regimens, and provided written informed consent,
- Subject is required to meet one of the following criteria for confirmation of a novel coronavirus infection with pneumonia: 1.The detection of novel coronavirus nucleic acid is positive in respiratory or blood specimens by Real-time -PCR, 2. Virus gene sequencing of respiratory or blood specimen is highly homologous with known novel coronavirus,
- Chest image confirmed pulmonary involvement;
- fever: ≥36.7℃ under the armpit, ≥38.0℃ in the oral cavity or ≥38.6℃ in the rectum and eardrum; • respiratory frequency ≥24 times/min or at least one cough;
- Onset time ≤14 days;
- Agree not to participate in another study until completion of the 14-day study; If you need to withdraw from this study;
- The subjects had not taken aspirin for nearly one month prior to the screening period.
- Can follow the study or follow up procedure. –
Exclusion Criteria:
- Women who have recently been pregnant or breast-feeding.
- Having a history of active gastrointestinal bleeding in the past 3 months.
- Blood routine examination showed that the platelet count was < 30×109/L.
- Patients with coagulation disorders.
- Unable to understand the potential risks and benefits of the study, and unable to follow up the evaluation as required.
- Having no capacity for civil conduct.
- A history of drug or alcohol abuse.
- Allergic to aspirin.
- Influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human partial lung virus, mycoplasma pneumoniae, chlamydia pneumonia, bacterial pneumonia, organized pneumonia, etc.
- Patients with cardiac stent placement (< 1 year).
- Any more complex medical problems that may interfere with research behavior or lead to increased risk, such as malignant tumors, blood diseases, liver diseases, AIDS, viral hepatitis, etc.
Contacts and Locations
Go to
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04365309
Locations
| China, Shaanxi |
| Cai Yue |
| Xi’an, Shaanxi, China, 710032 |
Sponsors and Collaborators
Xijing Hospital
Investigators
| Principal Investigator: | Cai Yue | the first affiliated hospital of the Air force medical university |
More Information
Go to
| Responsible Party: | Xijing Hospital |
| ClinicalTrials.gov Identifier: | NCT04365309 History of Changes |
| Other Study ID Numbers: | Xi jingH |
| First Posted: | April 28, 2020 Key Record Dates |
| Last Update Posted: | April 28, 2020 |
| Last Verified: | March 2020 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Xijing Hospital:
Novel coronavirus pneumonia
Aspirin
Protective effect
Additional relevant MeSH terms:
| COVID-19 Pneumonia Coronavirus Infections Respiratory Tract Infections Infections Pneumonia, Viral Virus Diseases Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases Aspirin Anti-Inflammatory Agents, Non-Steroidal | Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Antipyretics |
Other benefits of aspirin
The benefits of aspirin far exceed temporary relief from fever, aches, and pains. Most people know that it can protect you from a heart attack or stroke, if taken properly. Research suggests that it can reduce the risk of some cancers and Alzheimer’s disease. But aspirin has many other potential health, beauty, and personal benefits. Discover some of the amazing things that bottle in your medicine cabinet can do for you.
1. Treats skin conditions. Used as far back as the fifth century B.C. by Hippocrates to ease aches and pains, salicylic acid, a derivative of acetylsalicylic acid (aspirin), is a powder extracted from the bark of a willow tree. It “helps remove excess oil and exfoliate dead cells on the skin’s surface,” says Joshua Zeichner, MD, director of cosmetic and clinical research in dermatology at Mount Sinai Hospital in New York City, adding that it’s “extremely useful in treating acne.”
By dissolving dead skin and helping to shed the skin’s top layer, salicylic acid reduces the possibility of clogged pores – the common culprit behind breakouts. It also clears up redness and decreases swelling, which can alleviate symptoms of rosacea. People with psoriasis may also benefit from the salicylic acid in aspirin. “It can make psoriasis lesions thinner and can help reduce itch,” says Dr. Zeichner.
To make your own aspirin-based skin mask, crush up five uncoated aspirin pills and drop them into a quarter-cup of warm, distilled water. Stir well until the concoction develops a paste-like consistency. If you want, you can add a teaspoon of honey to the mix to reap the benefits of this natural antibacterial moisturizer. Once the mixture is about the same temperature as your skin, apply to any parts of the body affected by acne or other kinds of inflammation, and leave on for about 10 minutes. Wash off with warm water.
2. Gets rid of dandruff. Because of its moisturizing qualities, the same salicylic acid contained in face washes is also an ingredient in many dandruff shampoos. “Applying aspirin mixed with shampoo to your scalp may help reduce scalp inflammation that causes dandruff and help exfoliate flakes on the skin,” says Zeichner.
To make the concoction, crush two or three uncoated aspirins and mix them into the normal amount of shampoo used each time you wash your hair. Focus on your scalp as you massage the mixture into hair and let it sit for three to five minutes before rinsing.
3. Soothes stings and bites. Zeichner says aspirin, with its anti-inflammatory properties, may help reduce the redness, swelling, and pain from bug bites. Make an aspirin paste similar to the one used for problem skin or just dampen an uncoated aspirin and apply it to the affected area for a few minutes.
4. Removes stains. The salicylic acid in aspirin helps to neutralize stains by attacking the compounds found in sweat and breaking them down. Mix three crushed aspirins and half a cup of warm water in a bowl. Submerge the stained portion of the clothing into the bowl for a few hours. Afterwards, wash the shirt as usual. You can use any of the leftover mixture to remove nicotine or grass stains from hands by applying the solution and letting it sit for 15 minutes before washing hands thoroughly.
5. Makes your garden grow. Aspirin works just as well outside as it does on your skin by activating the plants’ natural defenses and preventing the formation of fungus. It also increases growth rate. Dissolve an uncoated aspirin in one gallon of water and spray onto any indoor and outdoor plants. It can also help prolong the life of fresh cut flowers. According to Judy Jernstedt, professor of plant sciences at UC Davis, the “salicylic acid reduces ethylene production, and with less ethylene present, floral senescence is delayed and the flowers last longer. The anti-fungal properties of salicylic acid dissolved in the vase water may also slow growth of mold, which if it enters the cut stem, can damage or clog the vascular tissue.” So be sure to add a ground aspirin to the water for your floral arrangement.
